nach oben

Strahlentherapie und Onkologie

Erschienen in:

01.03.2012 | Original article

Adjuvant intensity-modulated proton therapy in malignant pleural mesothelioma

A comparison with intensity-modulated radiotherapy and a spot size variation assessment

verfasst von: S. Lorentini, M. Amichetti, L. Spiazzi, S. Tonoli, S.M. Magrini, F. Fellin, M. Schwarz, PhD

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Intensity-modulated radiation therapy (IMRT) is the state-of-the-art treatment for patients with malignant pleural mesothelioma (MPM). The goal of this work was to assess whether intensity-modulated proton therapy (IMPT) could further improve the dosimetric results allowed by IMRT.

Patients and methods

We re-planned 7 MPM cases using both photons and protons, by carrying out IMRT and IMPT plans. For both techniques, conventional dose comparisons and normal tissue complication probability (NTCP) analysis were performed. In 3 cases, additional IMPT plans were generated with different beam dimensions.

Results

IMPT allowed a slight improvement in target coverage and clear advantages in dose conformity (p < 0.001) and dose homogeneity (p = 0.01). Better organ at risk (OAR) sparing was obtained with IMPT, in particular for the liver (D_mean reduction of 9.5 Gy, p = 0.001) and ipsilateral kidney (V₂₀ reduction of 58%, p = 0.001), together with a very large reduction of mean dose for the contralateral lung (0.2 Gy vs 6.1 Gy, p = 0.0001). NTCP values for the liver showed a systematic superiority of IMPT with respect to IMRT for both the esophagus (average NTCP 14% vs. 30.5%) and the ipsilateral kidney (p = 0.001). Concerning plans obtained with different spot dimensions, a slight loss of target coverage was observed along with sigma increase, while maintaining OAR irradiation always under planning constraints.

Conclusion

Results suggest that IMPT allows better OAR sparing with respect to IMRT, mainly for the liver, ipsilateral kidney, and contralateral lung. The use of a spot dimension larger than 3 × 3 mm (up to 9 × 9 mm) does not compromise dosimetric results and allows a shorter delivery time.

Ahamad A, Stevens CW, Smythe WR et al (2003) Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 55:768–775PubMedCrossRef

Alber M, Birkner M, Laub W et al (2000) Hyperion: an integrated IMRT planning tool. In: Schlegel W, Bortfeld T (eds) Proceedings of 13th International Conference on the Use of Computers in Radiation Therapy. Springer, Heidelberg, Germany, pp 46–48

Allen AM, Czerminska M, Janne PA et al (2006) Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys 65:640–645PubMedCrossRef

Allen AM, Schofield D, Hacker F et al (2007) Restricted field IMRT dramatically enhances IMRT planning for mesothelioma. Int J Radiat Oncol Biol Phys 69:1587–1592PubMedCrossRef

Allen AM, Den R, Wong JS et al (2007) Influence of radiotherapy technique and dose on patterns of failure for mesothelioma patients after extrapleural. Int J Radiat Oncol Biol Phys 68:1366–1374PubMedCrossRef

Baldini EH, Recht A, Strauss GM et al (1997) Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 63:334–338PubMedCrossRef

Belderbos J, Heemsbergen W, Hoogeman M et al (2005) Acute esophageal toxicity in non-small cell lung cancer patients after high dose conformal radiotherapy. Radiother Oncol 75:157–164PubMedCrossRef

Buduhan G, Menon S, Aye R et al (2009) Trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 88:870–876PubMedCrossRef

Dessy F, Linthout N, Gillis S, Closset M (2011) IBA proton pencil beam scanning: validation. Radiother Oncol 99(Supp1):S529CrossRef

10.

Dawson LA, Normolle D, Balter JM et al (2002) Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 53:810–821PubMedCrossRef

11.

Dhalluin X, Scherpereel A (2010) Treatment of malignant pleural mesothelioma: current status and future directions. Monaldi Arch Chest Dis 73:79–85PubMed

12.

Emami B, Lyman J, Brown A et al (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21:109–122PubMedCrossRef

13.

Forster KM, Smythe WR, Starkschall G et al (2003) Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation. Int J Radiat Oncol Biol Phys 55:606–616PubMedCrossRef

14.

Haber SE, Haber JM (2010) Malignant mesothelioma: a clinical study of 238 cases. Ind Health 49:166–172PubMedCrossRef

15.

Hentschel B, Oehler W, Strauss D et al (2011) Definition of the CTV prostate in CT and MRI by using CT-MRI image fusion in IMRT planning for prostate cancer. Strahlenther Onkol 187:183–190PubMedCrossRef

16.

Hillbrand M, Georg D (2010) Assessing a set of optimal user interface parameters for intensity-modulated proton therapy planning. J Appl Clin Med Phys 11:93–104

17.

Inoue T, Oh RJ, Shiomi H (2011) New approach for treatment of vertebral metastases using intensity-modulated radiotherapy. Strahlenther Onkol 187:108–113PubMedCrossRef

18.

Jeleń U, Alber M (2007) A finite size pencil beam algorithm for IMRT dose optimization: density corrections. Phys Med Biol 52:617–633PubMedCrossRef

19.

Krayenbuehl J, Oertel S, Davis JB, Ciernik IF (2007) Combined photon and electron three-dimensional conformal versus intensity-modulated radiotherapy with integrated boost for adjuvant treatment of malignant pleural mesothelioma after pleuropneumonectomy. Int J Radiat Oncol Biol Phys 69:1593–1599PubMedCrossRef

20.

Krayenbuehl J, Hartmann M, Lomax AJ et al (2010) Proton therapy for malignant pleural mesothelioma after extrapleural pleuropneumonectomy. Int J Radiat Oncol Biol Phys 78:628–634PubMedCrossRef

21.

Kristensen CA, Nøttrup TJ, Berthelsen AK et al (2009) Pulmonary toxicity following IMRT after extrapleural pneumonectomy form malignant pleural mesothelioma. Radiother Oncol 92:96–99PubMedCrossRef

22.

Lomax A (1999) Intensity modulation methods for proton radiotherapy. Phys Med Biol 44:185–206PubMedCrossRef

23.

Lucchi M, Chella A, Melfi F et al (2007) A phase II study of intrapleural immunochemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy, and long-term subcutaneous IL-2 in stage II–III malignant pleural mesothelioma. 31:229–234 (editorial comment 234–235)

24.

Marks LB, Bentzen SM, Deasy JO et al (2010) Radiation dose–volume effects in the lung. Int J Radiat Oncol Biol Phys 73:70–76CrossRef

25.

Miles EF, Larrier NA, Kelsey CR et al (2008) Intensity-modulated radiotherapy for resected mesothelioma: the Duke experience. Int J Radiat Oncol Biol Phys 71:1143–1150PubMedCrossRef

26.

Mirabelli D, Cavone D, Merler E et al (2010) Non-occupational exposure to asbestos and malignant mesothelioma in the Italian National Registry of Mesotheliomas. Occup Environ Med 67:792–794PubMedCrossRef

27.

Münter MW, Nill S, Thilmann C et al (2003) Stereotactic intensity-modulated radiation therapy (IMRT) and inverse treatment planning for advanced pleural mesothelioma. Feasibility and initial results. Strahlenther Onkol 179:535–541PubMedCrossRef

28.

Pinkawa M, Piroth MD, Holy R et al (2011) Combination of dose escalation with technological advances (intensity-modulated and image-guided radiotherapy) is not associated with increased morbidity for patients with prostate cancer. Strahlenther Onkol 187:479–484PubMedCrossRef

29.

Pinto C, Ardizzoni A, Betta PG et al (2011) Expert opinions of the First Italian Consensus Conference on the management of malignant pleural mesothelioma. Am J Clin Oncol 34:99–109PubMedCrossRef

30.

Rice DC, Craig WS, Correa AM (2007) Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg 84:1685–1693PubMedCrossRef

31.

Rice DC, Smythe WR, Liao Z et al (2007) Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 69:350–357PubMedCrossRef

32.

Rusch VW, Rosenzweig K, Venkatraman E et al (2001) A phase II trial of surgical resection and adjuvant high-dose hemitoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 122:788–795PubMedCrossRef

33.

Scorsetti M, Bignardi M, Clivio A et al (2010) Volumetric modulation arc radiotherapy compared with static gantry intensity-modulated radiotherapy for malignant pleural mesothelioma tumor: a feasibility study. Int J Radiat Oncol Biol Phys 77:942–349PubMedCrossRef

34.

Soukup M, Fippel M, Alber M (2005) A pencil beam algorithm for intensity modulated proton therapy derived from Monte-Carlo simulations. Phys Med Biol 50:5089–5104PubMedCrossRef

35.

Sterzing F, Sroka-Perez G, Schubert K et al (2008) Evaluating target coverage and normal tissue sparing in the adjuvant radiotherapy of malignant pleural mesothelioma: helical tomotherapy compared with step-and-shoot IMRT. Radiother Oncol 86:251–257PubMedCrossRef

36.

Sterzing F, Schubert K, Sroka-Perez G et al (2008) Helical tomotherapy. Experiences of the first 150 patients in Heidelberg. Strahlenther Onkol 184:8–14PubMedCrossRef

37.

Stevens CW, Forster K, Zhu X et al (2005) Excellent local control and survival after extrapleural pneumonectomy and IMRT for mesothelioma. Int J Radit Oncol Biol Phys 63:103–104CrossRef

38.

Stieler F, Wolff D, Bauer L et al (2011) Reirradiation of spinal column metastases: comparison of several treatment techniques and dosimetric validation for the use of VMAT. Strahlenther Onkol 187:406–415PubMedCrossRef

39.

Straif K, Benbrahim-Tallaa L, Baan R et al (2009) A review of human carcinogens – part C: metals, arsenic, dusts, and fibres. Lancet Oncol 10:453–454PubMedCrossRef

40.

Tonoli S, Vitali P, Scotti V et al (2011) Adjuvant radiotherapy after extrapleural pneumonectomy for mesothelioma. Prospective analysis of a multi-institutional series. Radiother Onkol 101:311–315CrossRef

41.

Tsao AS, Wistuba I, Roth JA, Kindler HL (2009) Malignant pleural mesothelioma. J Clin Oncol 27:2081–2090PubMedCrossRef

42.

Vandenbroucke E, Praet M, Vermaelen K et al (2009) Trimodality treatment of early stage malignant pleural mesothelioma (MPM): a single institution experience. J Thorac Oncol 4:S778CrossRef

43.

Xu ZY, Liang SX, Zhu J et al (2006) Prediction of radiation-induced liver disease by Lyman normal-tissue complication probability model in three-dimensional conformal radiation therapy for primary liver carcinoma. Int J Radiat Oncol Biol Phys 65:189–195PubMedCrossRef

Titel: Adjuvant intensity-modulated proton therapy in malignant pleural mesothelioma
A comparison with intensity-modulated radiotherapy and a spot size variation assessment
verfasst von: S. Lorentini
M. Amichetti
L. Spiazzi
S. Tonoli
S.M. Magrini
F. Fellin
M. Schwarz, PhD
Publikationsdatum: 01.03.2012
Verlag: Springer-Verlag
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 3/2012
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-011-0038-3

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Adjuvant intensity-modulated proton therapy in malignant pleural mesothelioma

A comparison with intensity-modulated radiotherapy and a spot size variation assessment

Abstract

Purpose

Patients and methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Patients and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

High expression of nuclear survivin and Aurora B predicts poor overall survival in patients with head and neck squamous cell cancer

RapidArc combined with the active breathing coordinator provides an effective and accurate approach for the radiotherapy of hepatocellular carcinoma

Re-irradiation combined with capecitabine in locally recurrent squamous cell carcinoma of the head and neck

Radiation-induced changes in breathing frequency and lung histology of C57BL/6J mice are time- and dose-dependent

Evidenz für den Einsatz moderner Bestrahlungstechniken beim nicht-kleinzelligen Bronchialkarzinom: unnötig, ungenügend, ausreichend oder zu spät?

Concerning the final report “Hyperthermia: a systematic review” of the Ludwig Boltzmann Institute for Health Technology Assessment, Vienna, March 2010

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie